I agree...what ever the case might about how or why ATRYN got approved, it's approved and can be sold. As long as people don't have adverse reactions to it, all is good in the European 'hood. Also look for off label uses. That could really be a huge boon for all companies involved, including GTCB. And if results for ATRYN are really spectacular, one can hope it will speed along FDA approval (FDA really needs to be overhauled).
Market Data 
Markets 
AI
